Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Neoadjuvant Chemotherapy in Advanced Cervical Cancer
NCT05173272Phase 3Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in Cervical Cancer (CC), sponsored by Sichuan Cancer Hospital. Started Jul 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05173272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173272.